CD47 and neoplasm: As with targeting CD4, designing multipronged CAR-T cells under a subsequent “HELP” gate framework, where a CD47 CAR assists T cells to bind with tumor cells first, followed by the ligation of the second CAR with another target antigen, may be possible.